36 studies found for:    C21005
Show Display Options
Rank Status Study
1 Completed Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
2 Completed
Has Results
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride;   Drug: Atomoxetine Hydrochloride;   Drug: Placebo Comparator
3 Active, not recruiting A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Chemotherapy;   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab [Herceptin]
4 Active, not recruiting Trastuzumab in Treating Women With Primary Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Procedure: adjuvant therapy
5 Active, not recruiting Eslicarbazepine Acetate Monotherapy Long Term Study
Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate
6 Completed A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
Condition: Schizophrenia
Interventions: Drug: bitopertin [RO4917838];   Drug: olanzapine;   Drug: placebo
7 Recruiting A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Placebo;   Drug: CP690,550;   Drug: CP-690,550
8 Completed Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC
Condition: Carcinoma, Renal Cell
Intervention: Drug: Gemcitabine, Capecitabine and Sorafenib (6 cycles)
9 Active, not recruiting Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate (BIA 2-093);   Drug: Placebo
10 Recruiting Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: CP-690,550
11 Completed A Study of Intravenous Mircera for the Maintenance Treatment of Hemodialysis Patients With Chronic Renal Anemia
Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: Epoetin alfa
12 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
13 Active, not recruiting A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Condition: Crohn's Disease
14 Enrolling by invitation Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BIIB019 (Daclizumab High Yield Process)
15 Recruiting A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib;   Drug: Placebo
16 Recruiting A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib;   Drug: Placebo
17 Completed A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: aleglitazar
18 Completed Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
Condition: Hypertension
Interventions: Drug: Candersartan;   Drug: Nifedipine (Adalat, BAYA1040);   Drug: Nifedipine GITS/Candersartan;   Drug: Placebo
19 Completed Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Condition: Tourette's Disorder
Intervention: Drug: aripiprazole
20 Active, not recruiting A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif;   Drug: Rebif placebo;   Drug: ocrelizumab;   Drug: ocrelizumab placebo

Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results
Indicates status has not been verified in more than two years